Skip to main content

Table 1 Socio-demographic and Clinical characteristics of HIV/AIDs patients in the University of Gondar referral hospital, 2017

From: Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia

Variables

Frequency

Percent

Age

18–29

54

12.8

30–39

169

40.0

40–49

136

32.2

> = 50

64

15.1

Marital status

Single

97

22.9

Married

209

49.4

Divorced

81

19.1

Widowed

36

8.5

Gender

Female

272

64.3

Male

151

35.7

Resident

Urban

343

81.1

Rural

80

18.9

Occupation

Farmer

51

12.1

Merchant

58

13.7

Student

17

4

government employ

43

10.2

daily laborer

62

14.7

house life

101

23.9

Private employ

66

15.6

Other

25

5.9

Educational status

Illiterate

121

28.6

primary school

117

27.7

secondary school

142

33.6

Tertiary

43

10.2

Religion

Orthodox

386

91.3

Muslim

30

7.1

Protestant

7

1.7

Total

423

100.0

Duration of ART in year

<=6

162

38.3

> 6

261

61.7

Mean ART duration in year

7 year (+ 3)

423

100%

Base line WHO stage

WHO stage I

57

(13.5)

WHO stage II

97

(22.9)

WHO stage III

214

(50.6)

WHO stage IV

55

(13.0)

WHO stage during data collection

WHO stage I

11

(2.6)

WHO stage II

408

(96.5)

WHO stage III

4

(.9)

Type of Opportunistic infection

No

308

(72.8)

Protozoa

4

(.9)

Helminths

12

(2.8)

Hepatitis viruses

3

(.7)

fungal infections

1

(.2)

TB

89

(21.0)

Mixed

6

(1.4)

Initial regimen

D4T + 3TC + NVP

78

(18.4)

D4T + 3TC+ EFV

29

(6.9)

AZT +3TC + NVP

156

(36.9)

AZT + 3TC + EFV

30

(7.1)

TDF + 3TC + EFV

87

(20.6)

TDF + 3TC + NVP

31

(7.3)

D4T + 3TC + NVP

6

(1.4)

Pediatric 4C (AZT + 3TC + NVP)

6

(1.4)

Switching

No

261

(61.7)

Yes

162

(38.3)

Total

423

(100.0)

Switching

To 1st line drug

150

(35.5)

To 2nd line drug

12

(2.8)

Second regimen

AZT +3TC + NVP

61

37.7

AZT + 3TC + EFV

25

15.4

TDF + 3TC + NVP

25

15.4

TDF + 3TC + EFV

39

24.1

ABC + ddl + LPV/R

11

6.8

TDF + ddl + IPV/R

1

.6

Reason of switching drug

Toxicity

109

(67.3)

Pregnancy

7

(4.3)

TB

18

(11.1)

Clinical failure

1

(.6)

Age

9

(5.6)

ARV drug ADH at base line

Good

408

(96.5)

Fair

2

(.5)

Poor

13

(3.1)

ARV drug ADH During data collection

Good

420

(99.3)

Poor

3

(.7)

Base line CD4 count

<=199

267

(63.1)

200–349

120

(28.4)

350–499

27

(6.4)

> = 500

9

(2.1)

CD4 count during data collection

<=199

44

(10.4)

200–349

110

(26.0)

350–499

114

(27.0)

> = 500

155

36.6

Viral load count

Undetected

224

53.0

0–19

84

19.9

20–999

53

12.5

> = 1000

62

14.7

Total

423

100

Component of immunological failure

CD4 Falling More Than 50%

30

53.6

CD4 Falling Below Baseline

21

37.5

CD4 Persistently Below 100

5

8.9

Total

56

100

  1. ADH adherence, ARV Antiretroviral, D4T Stavudine,TDF TenofovirDisoproxilFumarate, AZT/ 3TC Zidovudine/Lamivudine, EFV Efavirenze, NVP Nevirapine, ABC abacavir, ddl didanosine, LPV/R lopinavir/ritonavir, Mixed patients infected with more than two organism